Insights · 26-TA-2066 · 16 November 2026
A joint contribution to clinical trial regulation
A result of collaboration between DEPCELL and SIA “Cilmes šūnu tehnoloģijas”: a company opinion and proposals submitted by Uldis Bērziņš through the TAP portal for safe, proportionate ATMP clinical trial regulation.

On 16 November 2026, SIA “Cilmes šūnu tehnoloģijas” submitted an opinion on draft 26-TA-2066, “Regulations on clinical trials of medicinal products for human use”, through Latvia’s TAP portal. The official document identifies Uldis Bērziņš as the author of seven objections and one proposal.
The collaboration aims to reduce avoidable administrative and financial burdens while preserving patient protection, medicinal product quality and reliable data. The proposals address duplicate information requests, separation of trial and standard-care costs, insurance, SME support, and a clear distinction between ATMP clinical trials, orphan designation and hospital exemption.
Company opinion
Word document prepared on draft 26-TA-2066.
Uldis Bērziņš’s submission
7 objections and 1 proposal published on TAP.
Assessment of proposals
Decisions on the proposals rest with the responsible authorities.
The TAP opinion was submitted on 16 November 2026. The status “Nesaskaņots” records the company’s non-endorsement of the draft. It does not establish that the Ministry rejected the opinion or that the proposals have been adopted. This is a contribution to regulatory development, not a treatment authorisation or evidence of clinical efficacy.
Documents and sources
Approved investors can read the complete, unchanged Latvian Word text of 13 November and all eight TAP entries. The dossier includes English reading versions alongside the original Latvian records.

